Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children

Vaccine

Volumn 29, Issue 47, 2011, Pages 8705-8711

  Phongsamart, Wanatpreeya ^a   Sirisanthana, Virat ^b   Wittawatmongkol, Orasri ^a   Maleesatharn, Alan ^a   Sudjaritruk, Tavitiya ^c   Chearskul, Pimpannada ^a   Aurpibul, Linda ^b   Sirisanthana, Thira ^b   Chokephaibulkit, Kulkanya ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

HIV infected children; Influenza vaccine; Pandemic H1N1 vaccine; Thailand

Indexed keywords

ANTIRETROVIRUS AGENT; CROSS REACTING ANTIBODY; INFLUENZA VACCINE;

ADOLESCENT; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFLUENZA A (H1N1); MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; THAILAND;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HIV INFECTIONS; HUMANS; IMMUNIZATION, SECONDARY; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; THAILAND; VACCINATION;

EID: 82455192719     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.101     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention Outbreak of swine-origin influenza A (H1N1) virus infection - Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep 2009, 58(17):467-470.
2. Centers for Disease Control and Prevention Swine influenza A (H1N1) infection in two children - Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep 2009, 58(15):400-402.
3. Sachedina N., Donaldson L.J. Paediatric mortality related to pandemic influenza A H1N1 infection in England: an observational population-based study. Lancet 2010, 376(9755):1846-1852.
4. Shieh W.J., Blau D.M., Denison A.M., Deleon-Carnes M., Adem P., Bhatnagar J., et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol 2010, 177(1):166-175.
5. Feiterna-Sperling C., Edelmann A., Nickel R., Magdorf K., Bergmann F., Rautenberg P., et al. Pandemic influenza A (H1N1) outbreak among 15 school-aged HIV-1-infected children. Clin Infect Dis 2010, 51(11):e90-e94.
6. Riera M., Payeras A., Marcos M.A., Viasus D., Farinas M.C., Segura F., et al. Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicenter study. AIDS 2010, 24(16):2461-2467.
7. Larcombe P.J., Moloney S.E., Schmidt P.A. Pandemic (H1N1) 2009: a clinical spectrum in the general paediatric population. Arch Dis Child 2011, 96(1):96-98.
8. Libster R., Bugna J., Coviello S., Hijano D.R., Dunaiewsky M., Reynoso N., et al. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N Engl J Med 2010, 362(1):45-55.
9. Klein M.B., Lu Y., DelBalso L., Cote S., Boivin G. Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis 2007, 45(2):234-240.
10. Ormsby C.E., de la Rosa-Zamboni D., Vázquez-Pérez J., Ablanedo-Terrazas Y., Vega-Barrientos R., Gómez-Palacio M., et al. Severe 2009 pandemic influenza A (H1N1) infection and increased mortality in patients with late and advanced HIV disease. AIDS 2011, 25(4):435-439.
11. Lin J.C., Nichol K.L. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001, 161(3):441-446.
12. Kunisaki K.M., Janoff E.N. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009, 9(8):493-504.
13. Centers for Disease Control and Prevention Update on influenza A (H1N1) 2009 monovalent vaccines. MMWR Morb Mortal Wkly Rep 2009, 58(39):1100-1101.
14. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361(25):2405-2413.
15. Dolin R. Editorial commentary: perspectives on the role of immunization against influenza in HIV-infected patients. Clin Infect Dis 2011, 52(1):147-149.
16. Viganò A., Zuccotti G.V., Pacei M., Erba P., Castelletti E., Giacomet V., et al. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 48(3):289-296.
17. Zanetti A.R., Amendola A., Besana S., Boschini A., Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine 2002, 20(Suppl. 5):B29-B32.
18. Bickel M., Wieters I., Khaykin P., Nisius G., Haberl A., Stephan C., et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010, 24(9):F31-F35.
19. Crum-Cianflone N.F., Eberly L.E., Duplessis C., Maguire J., Ganesan A., Faix D., et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011, 52(1):138-146.
20. Tebas P., Frank I., Lewis M., Quinn J., Zifchak L., Thomas A., et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 2010, 24(14):2187-2192.
21. Iamsirithaworn S., Akarasewi P., Yingyong T., Suthachana S., Pittayawonganon C., Ungchusak K. Three Waves of the 2009 H1N1 Infl uenza Pandemic in Thailand. Siriraj Med J 2011, 63:64-67.
22. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361(25):2414-2423.
23. Lerdsamran H., Pittayawonganon C., Pooruk P., Mungaomklang A., Iamsirithaworn S., Thongcharoen P., et al. Serological response to the 2009 pandemic influenza A (H1N1) virus for disease diagnosis and estimating the infection rate in Thai population. PLoS One 2011, 6(1):e16164.
24. Centers for Disease Control and Prevention 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994, 43(RR-12):1-10.
25. Centers for Disease Control and Prevention Official authorized addenda: human immunodeficiency virus infection codes and official guidelines for coding and reporting ICD-9-CM. MMWR Morb Mortal Wkly Rep 1994, 43(RR-12):11-19.
26. Giannattasio A., Lo Vecchio A., Russo M.T., Pirozzi M.R., Barbarino A., Ruberto E., et al. Pandemic flu: a comparative evaluation of clinical, laboratory, and radiographic findings in HIV-positive and negative children. AIDS 2010, 24(14):2292-2294.
27. Kroon F.P., Rimmelzwaan G.F., Roos M.T., Osterhaus A.D., Hamann D., Miedema F., et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS 1998, 12(17):F217-F223.
28. Nolan T., McVernon J., Skeljo M., Richmond P., Wadia U., Lambert S., et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010, 303(1):37-46.
29. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375(9708):56-66.
30. Fowke K.R., D'Amico R., Chernoff D.N., Pottage J.C., Benson C.A., Sha B.E., et al. Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients. AIDS 1997, 11(8):1013-1021.
31. Lyall E.G., Charlett A., Watkins P., Zambon M. Response to influenza virus vaccination in vertical HIV infection. Arch Dis Child 1997, 76(3):215-218.
32. Iorio A.M., Francisci D., Camilloni B., Stagni G., De Martino M., Toneatto D., et al. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine 2003, 21(25-26):3629-3637.
33. Bickel M., von Hentig N., Wieters I., Khaykin P., Nisius G., Haberl A., et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis 2011, 52(1):122-127.
34. Weinberg A., Muresan P., Fenton T., Handelsman E., Watts H., Miller J., et al. Safety and immunogenicity of two dose of monovalent Pandemic H1N1 (pH1N1) influenza vaccine in HIV-infected pregnant women. 48th infectious disease society of America 2010, [Abstract LB-14].
35. Flynn P., Nachman S., Spector S.A., Cunningham C., Weinberg A., Pass R., et al. Safety and immunogenicity of 2009 H1N1 influenza immunization in HIV-1 perinatally infected children and youth. 48th infectious disease society of America 2010, [Abstract LB-40].
36. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361(25):2424-2435.
37. McVernon J., Laurie K., Barr I., Kelso A., Skeljo M., Nolan T. Absence of cross-reactive antibodies to influenza A (H1N1) 2009 before and after vaccination with 2009 Southern Hemisphere seasonal trivalent influenza vaccine in children aged 6 months-9 years: a prospective study. Influenza Other Respi Viruses 2011, 5(1):7-11.
38. Lee V.J., Tay J.K., Chen M.I., Phoon M.C., Xie M.L., Wu Y., et al. Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains. Vaccine 2010, 28(42):6852-6857.
39. Centers for Disease Control and Prevention Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009. MMWR Morb Mortal Wkly Rep 2009, 58(48):1351-1356.
40. WHO Global advisory committee on vaccine safety, 3-4 December 2009. Wkly Epidemiol Rec 2010, 85(5):29-33.